- Home
- IOBT vs SNTI Comparison
IOBT vs SNTI Comparison
Compare IOBT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- SNTI
- Stock Information
- Founded
- IOBT 2014
- SNTI 2016
- Country
- IOBT Denmark
- SNTI United States
- Employees
- IOBT N/A
- SNTI N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- SNTI Health Care
- Exchange
- IOBT Nasdaq
- SNTI Nasdaq
- Market Cap
- IOBT 79.7M
- SNTI 85.3M
- IPO Year
- IOBT 2021
- SNTI N/A
- Fundamental
- Price
- IOBT $1.60
- SNTI $3.22
- Analyst Decision
- IOBT Strong Buy
- SNTI Strong Buy
- Analyst Count
- IOBT 3
- SNTI 1
- Target Price
- IOBT $9.33
- SNTI $12.00
- AVG Volume (30 Days)
- IOBT 147.9K
- SNTI 27.9K
- Earning Date
- IOBT 05-14-2025
- SNTI 05-06-2025
- Dividend Yield
- IOBT N/A
- SNTI N/A
- EPS Growth
- IOBT N/A
- SNTI N/A
- EPS
- IOBT N/A
- SNTI N/A
- Revenue
- IOBT N/A
- SNTI N/A
- Revenue This Year
- IOBT N/A
- SNTI N/A
- Revenue Next Year
- IOBT N/A
- SNTI N/A
- P/E Ratio
- IOBT N/A
- SNTI N/A
- Revenue Growth
- IOBT N/A
- SNTI N/A
- 52 Week Low
- IOBT $0.66
- SNTI $1.52
- 52 Week High
- IOBT $1.73
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IOBT 78.81
- SNTI 44.57
- Support Level
- IOBT $1.09
- SNTI $3.03
- Resistance Level
- IOBT $1.29
- SNTI $3.50
- Average True Range (ATR)
- IOBT 0.12
- SNTI 0.21
- MACD
- IOBT 0.05
- SNTI 0.00
- Stochastic Oscillator
- IOBT 88.21
- SNTI 23.40
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.